Golan T et al. Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm). Gastrointestinal Cancers Symposium 2021;Abstract 420.

Golan T et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Gastrointestinal Cancers Symposium 2021;Abstract 378.

Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Eng J Med 2019;381(4):317-27. Abstract

Noordermeer S, van Attikum H. PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells. Trends in Cell Biol 2019;29(10):820-34. Abstract

Pishvaian MJ et al. Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: Results from the Know Your Tumor program. JCO Precision Oncology 2019. Abstract

Ramanathan RK et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol 2019;37(13):1062-9. Abstract

Ranoa DRE et al. STING promotes homeostasis via regulation of cell proliferation and chromosomal stability. Cancer Res 2019;79(7):1465-79. Abstract

Reiss KA et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 2021;39(22):2497-505. Abstract

Shen J et al. PARPi Triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 2019;79(2):311-19. Abstract

Singhi AD et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 2019;156(8);2242-53. Abstract

Tempero MA et al. HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). ASCO 2020;Abstract 638

Vinayak S et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol 2019;5(8):1132-40. Abstract